Zealand plans €100 million IPO
This article was originally published in Scrip
Executive Summary
Zealand Pharma, the Danish peptide drug discovery company, has announced plans to raise up to €104 million at a pre-money valuation of between €215 million and €300 million in an IPO on the NASDAQ OMX Exchange in Copenhagen. This would be the largest Scandinavian life sciences IPO since 2000 and the first one outside of France this year. It would also more than double the amount raised by European life science companies in an IPO this year (see table).